The main cause of allogeneic hematopoietic cell transplant (HCT) failure is a disease relapse, which occurs in 15-55% of patients undergoing HCT for acute myeloid leukemia (AML). 1 Decreased incidence of malignancy relapse has been observed in patients who develop graft versus host disease (GVHD), presumably due to a concomitant graft-versus-leukemia/ lymphoma (GVL) reaction. T cells are believed to have a major role in the GVL reaction. 2 A small study has shown that leukemia antigen-specific T cells can be detected after HCT and that they are associated with decreased malignancy relapse. 3 However, only few leukemia specific antigens are known. A surrogate marker of the GVL response could, theoretically, be used instead. This could be the immune response to another endogenous antigen like an antigen from a persisting virus (for example, a herpesvirus) that infected the recipient long before the transplantation. Parkman et al, showed an association between high proliferative response of mononuclear cells (MNCs) to herpesvirus lysate and decreased risk of relapse. 4 However, they included only cord blood transplant recipients, which accounts for a minority of HCT recipients, did not assess which MNC subset is associated with relapse, and did not assess whether the proliferative response could be used as a predictive marker of relapse. Here, we developed and tested in marrow or filgrastim-mobilized blood stem cell recipients the predictive value of assays enumerating subsets of herpesvirus-specific T cells. The subsets were defined by surface marker expression (CD4 or CD8) and their ability to proliferate or produce interleukin-2 (IL2), interferon gamma (IFNg) and/or tumor necrosis factor-a (TNFa) upon stimulation with viral antigens. To enable evaluation of the majority of patients we measured T cells specific for the three most prevalent herpesviruses, that is, Epstein-Barr virus (EBV), human herpesvirus 6 (HHV6) and Varicella-zoster virus (VZV).
We studied 42 AML patients. There were no statistically significant differences in clinical/demographic characteristics of patients who did versus did not relapse (Supplementary Table 1) . Minimum follow-up for relapse of non-relapse patients was 2 years (important, as most relapses occur in the first 2 years post transplant), except for two patients who were lost to follow-up on days 435 and 470 post transplant. On day 56, we enumerated 98 herpesvirus-specific T-cell subsets secreting cytokines after 18 h stimulation ('18 h assay'), and 14 subsets proliferating after 7-day stimulation ('7 d assay'). For details, see the Patients and Methods section in Supplementary Material, Supplementary Figures 1-3 and Supplementary Table 6 .
Fifteen of the 112 T-cell subsets enumerated (11%; CI, 9-24%; that is, significantly more than expected by chance) were significantly associated with relapse using Mann-Whitney-Wilcoxon (MWW) test (example shown in Supplementary  Figure 4 ). These subsets are listed in Table 1. Supplementary  Table 2 shows subsets that were not associated with relapse. All the 15 subsets had higher median counts in the no relapse compared with the relapse group. Thus, some herpesvirusspecific T-cell subsets were associated with relapse in AML patients. As shown in Table 1 , EBV-lysate-specific T-cell subsets were the most frequent to be associated with relapse, and accounted for 8 of the 15 subsets that were significantly associated with AML relapse (per MWW test). The majority of subsets determined in the 18 h assay and associated with relapse (9/12) were unifunctional. To identify which of the 15 subsets was (were) associated with relapse after adjustment for multiple comparisons, Westfall-Young analysis was performed. This identified one subset definitely associated with relapse (Po0.05)FBZLF1-specific CD4 T cells producing IFNg, and three subsets possibly associated with relapse (P between 0.05 and 0.15)FEBNA3-specific CD8 T cells producing IFNg and TNFa, EBNA3-specific CD8 T cells producing IFNg, and EBVlysate-specific CD8 T cells producing IFNg and IL2 (Table 1 and Figure 1a ). For each of these subsets a cutoff was set at the median value (the cutoffs are shown in Figure 1a) , and a score of one was given to patients with T-cell counts above the median, and a score of 0 was given to patients with T-cell counts equal to or below the median. The sensitivities, specificities, positive predictive value and negative predictive value for each subset are shown in Table 2 . The combination of the subsets associated with relapse could potentially yield a better prediction of subsequent relapse than each subset alone, as, for example, T-cell repertoire of some patients may be skewed towards BZLF1-specific T cells and of other patients towards EBNA3-specific T cells. We combined the scores from the four subsets identified by the Westfall-Young analysis as associated or possibly associated with relapse. The score derived from the combination was significantly higher in patients who did versus did not relapse (P ¼ 0.0001). A score of o1 had a sensitivity of 100%, specificity of 88%, negative predictive value (NPV) of 100% and positive predictive value (PPV) of 67% for subsequent relapse ( Figure 1b , Table 2 ). This was better than for BZLF1-specific CD4T cells producing IFNg, which was the best single marker ( Table 2) . Consistent with that, area under the receiveroperator characteristic (ROC) curve for the combined score was significantly higher than area under the ROC curve for the BZLFspecific CD4 T cells producing IFNg (P ¼ 0.02). A Kaplan-Meier plot showing the probability of developing relapse for patients with a score o1 is shown in Figure 2 . Multivariate analysis for the combined score could not be performed, as no patient with relapse had a score above zero. Instead, we divided the patients into whether they had poor (n ¼ 11) or good (n ¼ 31) disease stage pretransplant, as this is the strongest variable associated with relapse. Similar results were found when performing the analysis separately using patients with either good or poor prognosis disease stage at transplantation (Supplementary Figure 5) . Specifically, a score of o1 derived from the combination of four subsets was 100% sensitive and 86% specific and had a NPV ¼ 100% and PPV ¼ 80% in poor disease stage patients (P ¼ 0.02), and was 100% sensitive and 89% specific and had a NPV ¼ 100% and PPV ¼ 57% in good disease stage patients (P ¼ 0.004). The score was more predictive of relapse than disease stage (Supplementary Table 3 ). Finally we assessed if Letters to the Editor total CD4 or CD8 T-cell counts were significantly associated with relapse, but found no statistical significant association (Supplementary Figure 6) .
Development of GVHD is known to be associated with decreased likelihood of relapse. We therefore assessed whether there was a correlation between counts of herpesvirus-specific T-cell subsets on day 56 and development of significant GVHD (requiring systemic immunosuppressive treatment) after day 56.
Six of the 112 T-cell subsets showed a significant correlation with development of significant GVHD after day 56 (5%; CI, 2-11%; that is, not significantly more than expected by chance).
The ability to mount a T-cell response towards reactivating herpesviruses may be a surrogate marker for low propensity of patients to develop infections due to any pathogen. This was evaluated in a combined cohort of the AML patients (used for the analysis of association between herpesvirus-specific T cells Figure 1 Counts and score combination of the four herpesvirus-specific T-cell subsets associated or possibly associated with relapse in the Westfall-Young analysis. (a) The horizontal lines denote the cutoffs (medians of all patients, irrespective of whether they relapsed) used to decide whether the subset count was low (under the cutoff) or high (above the cutoff). Westfall-Young P values are shown. (b) T-cell subset counts were combined using a scoring system. A cutoff was determined as the median, and a T-cell subset count above the median was given a score of 1, and below the median was given a score of 0. Horizontal lines denote the median score for patients who did not relapse and the median for patients who relapsed. MWW P-value is shown.
Letters to the Editor and relapse) plus 23 non-Hodgkin lymphoma patients to maximize the power of the analysis. The characteristics of the combined cohort are shown in Supplementary Table 4 . Between days 56 and 365 post transplant we found a total of 64 infections of which 51 were microbiologically documented to be due to a virus (n ¼ 30), a bacterium (n ¼ 25) or a fungus (n ¼ 9). Counts of 14 of 98 T-cell subsets enumerated by the 18 h assay (14%; CI, 8-23%) showed a negative correlation with the rate of any infection, suggesting an association between low herpesvirusspecific T-cell counts and infections (Supplementary Table 5) . Surprisingly, counts of 4 of 14 herpesvirus-specific precursor cells enumerated by the 7-day assay (25%; CI, 7-52%) showed a positive correlation with any infection. Counts of 20 of 98 cytokine producing T-cell subsets (20%; CI, 13-30%) showed a negative correlation with the rate of viral infections, suggesting a highly significant association between herpesvirus-specific T-cell counts and viral infections. Counts of 8 of 98 cytokine producing T-cell subsets (8%; CI, 4-15%) showed a correlation (some positive, some negative) with the rate of bacterial infections. Counts of 4 of 98 cytokine producing T-cell subsets (4%; CI, 1-10%) showed a correlation (some positive, some negative) with the rate of fungal infections. This suggested no association between herpesvirus-specific T-cell counts and bacterial or fungal infections. By Westfall-Young permutation analysis, BZLF1-specific CD8 T cells producing IFNg and TNFa was the only subset that was possibly associated with the rate of viral infections (P ¼ 0.076), and no subset was associated with the rates of any infections, bacterial infections or fungal infections. Thus, consistent with the study of Parkman et al, 4 the association of herpesvirus-specific T cells was weaker for infections than for relapse. Below median counts of BZLF1-specific CD8 T cells producing IFNg and TNFa had a sensitivity of 74%, specificity of 60%, PPV of 44% and a NPV of 84% for developing at least one viral infection between days 56 and 365.
The aim of this study was to determine if counts of functional herpesvirus-specific T cells can be used as predictive markers for risk of malignancy relapse and infections. The association between herpesvirus-specific T cells and relapse has been described by Parkman et al in patients with ALL and AML who received cord blood transplantation. 4 Parkman et al showed an association between a positive proliferation response of MNCs when stimulated with herpesvirus lysates and a low likelihood of relapse or infections. However, the study was not designed to assess the predictive value of herpesvirus-specific responses, and they did not use viral lysates from the most prevalent herpesviruses. Finally, the study was performed in cord blood transplant recipients, which are a minority of all HCT recipients.
We enumerated counts of functional (expressing IFNg, TNFa and/or IL2 or proliferating) herpesvirus-specific T cells at one time point before when the majority of HCT recipients relapse. Our rationale for using herpesvirus-specific T cells as surrogate markers for overall immune recovery was that both tumor cells and virus-infected cells should present antigens to the donor immune system and the ability to mount an anti-viral response should correlate with the ability to mount an anti-tumor response. However, other explanations may exist. It has previously been shown that herpesvirus-specific T cells show alloreactivity 5 and thereby have a direct GVL effect. However, prolonged CMV viremia has been associated with increased relapse. 6 This is in agreement with our hypothesis, as the prolonged viremia may be a result of poor overall immune reconstitution, including the GVL response. It has also been suggested that reactivation of herpesviruses may provide the costimulation necessary for generating tumor-or host-specific T cells. 7 Other factors may also have a role in whether or not a patient relapses, including the growth potential/burden of leukemia or NK cell response to leukemic cells. 8 A negative correlation was observed between the counts of herpesvirus-specific T cells and the rates of viral infections (due to any virus). This is consistent with the expectation that Th1-type responses (characterized by IFNg, TNFa and IL2 production) are important for controlling viral infections. However, the correlation was not strong when adjusting for multiple comparisons using the Westfall-Young permutation Table 2 Sensitivity, specificity, positive predictive value and negative predictive value of herpesvirus-specific T-cell subsets that were associated or possibly associated with risk of relapse in W-Y analysis Sensitivity Specificity PPV NPV BZLF1-specific CD4 T cells producing IFNg  100%  64%  57%  100%  EBNA3-specific CD8 T cells producing IFNg  100%  68%  42%  100%  EBNA3-specific CD8 T cells producing IFNg+TNFa  100%  62%  38%  100%  EBV-lysate-specific CD8 T cells producing IFNg+IL2  100%  59%  36% Letters to the Editor analysis. No correlation was present between the counts of herpesvirus-specific T cells and bacterial or fungal infections, possibly, as Th2 rather than Th1 T-cell response helps to curb bacterial infections.
The major limitation of our study is the relatively low number of patients. Additionally, we selected patients who did not have GVHD on day 56 (as these patients would not be candidates for withdrawal of immunosuppressive drugs or donor lymphocyte infusion (DLI)), and excluded patients who developed second malignancy (as these patients are typically treated by modalities that alter their immunity). We did evaluate the counts of herpesvirus-specific T cells in the six patients excluded owing to second malignancy (mostly post transplant lymphoproliferative disorder (PTLD)), but did not show the data. All patients had a score of 0. Even if these patients were treated with preemptive treatment for relapse (that is, withdrawal of immunosuppression or DLI), they would likely benefit from the treatment, as withdrawal or decrease of immunosuppression or DLI are treatment options for PTLD.
In conclusion, we have shown that herpesvirus-specific T cells can indeed be a surrogate marker of the GVL response in AML patients. The ability to predict patients with increased risk of relapse could lead to preemptive therapy, such as withdrawal of immunosuppression or DLI and reduction in relapse rates. However, preemptive therapy can have adverse effects. The ability to clearly distinguish between patients at high versus low risk of relapse is therefore essential. Our assay has shown a high sensitivity, however, a better specificity would be desirable for guiding preemptive treatment. Perhaps, if combining our assay with an assay of high specificity albeit poor sensitivity (for example, a minimal residual disease assay), the best prediction of relapse could be achieved. Future studies including a higher number of patients and performed prospectively are necessary to confirm the clinical utility of these assays.
The primary goal of initial therapy in acute myeloid leukemia (AML) is the effective and prompt achievement of complete remission without excessive morbidity and mortality, paving the way for post-remission strategies, including allogeneic stem cell transplantation. High-dose cytarabine (HiDAC) is an established component of most treatment regimens for adult AML and is incorporated into either the induction or consolidation phase of intensive chemotherapy. HiDAC-based consolidation therapy significantly improves the survival of adult patients with AML up to the age of 60 years. Attempts to further improve treatment outcomes in AML have led to studies investigating the role of HiDAC during AML induction. Randomized comparisons have consistently shown that HiDAC-based induction chemotherapy results in a higher complete remission rate after the first cycle of therapy, compared with standard dose ara-C induction. Complete remission rates of 77% after a single induction cycle can be achieved using HiDAC in combination with idarubicin and etoposide, compared with 41-66% with standard dose ara-C. [1] [2] [3] Although HiDAC-based induction achieves good early disease control, the benefits are offset by excessive induction-related toxicity and an increased risk of early death compared with standard dose ara-C. The definition of induction-related death varies widely between reports, making cross-study comparisons difficult. In patients under the age of 60 years, standard dose ara-C-based induction is associated with an early mortality rate of between 6-13%. [4] [5] [6] Early mortality after HiDAC induction ranges between 7-18%. 3, 4, [6] [7] [8] Identification of baseline risk factors predictive of early treatment-related mortality in adult AML after HiDAC-based induction therapy in a cooperative group setting has not been
